2020 China BioMed Innovation and Investment Conference (2020 CBIIC) will be held on September 27-29 in Suzhou Industrial Park. CBIIC was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) as an annual dialogue between pharmaceutical innovation and investment in Asia Pacific.
Established by PhIRDA, and successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX), Chinese Hospital Association (CHA) and Research and Development International (RDI) from 2016 to 2019, CBIIC received great support from J.P. Morgan, Springer Nature and other international organizations. CBIIC covers hot topics and areas such as the latest industry policy analysis, cutting-edge innovation achievement, R&D hot spot at home and abroad and trend of investment and M&A.
By the end of 2019, over 10,000 participants from 2,100 pharmaceutical companies and 1,500 investment institutions have participated in the CBIIC. 33 new drugs made global first clinical trial data release, 450 innovative projects at home and abroad made roadshows in CBIIC events, including 80 international projects, receiving attention and praise worldwide. To facilitate the effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors, 2020 CBIIC will continue to provide the participants with One-on-One Partnering System, the well functional platform for close communication between innovators and investors.
2020 CBIIC Roadshow Application System is Officially Online Today!
(Participant Registration will open at the end of July)
With the biopharmaceutical industry being regarded as the national pillar, 2020 CBIIC will remain true to its original aspiration to promote the linkage between social capital and pharmaceutical innovation, design activities around the hot spots of pharmaceutical innovation, present the latest outcomes of innovation and analyze the new investment trend and industry policy. Excellent roadshows and parallel sessions covering biopharmaceutical, immunotherapy, AI for drug design, Big Data + WIT MED and innovative medical devices will be presented and meet diversified need of the participants.
Due to the limitation of roadshow projects, please apply as soon as possible.
CBIIC Website: http://cbiic.phirda.com
Please visit CBIIC Website on PC to apply for roadshow.
Deadline of Roadshow Application: July 20, 2020
Contact: Yang Yuanlin
Cell: +86 18511990895
Highlights of 2020 CBIIC
700+ Pharmaceutical Companies
500+ Investment and Financial Institutions
140+ Innovative Projects
20+ Excellent Parallel Sessions
Live Broadcast of Opening Ceremony
Focus on Latest Hot Topics
Domestic and Foreign KOLs
Face to Face Conversation with Investors
English-Chinese Simultaneous Interpretation
One-on-One Partnering System
Authoritative Domestic and Foreign Media Report
Hot Topics of 2020 CBIIC
Clinical Trial Data Release of Innovative Drugs
Latest Progress of Global Oncology Drug R&D
Biopharmaceutical Innovative Project
Financing M&A for Innovative Pharmaceutical Companies
Investors’ Experience Sharing
Rare Diseases and Orphan Drugs R&D
AI for Drug Design
Big Data + WIT MED
Innovative Medical Devices
Listed/Non-listed Companies Roadshow
Service Agencies Roadshow
China BioMed Innovation and Investment Conference (CBIIC)
Annual grand conference and platform for industry leaders, experts and investors to promote the communication between pharmaceutical industry and investment industry.
Supported by National Authorities and Preferred by Global KOLs
✦Government Officials and Industry Leaders
Senior Officials from National Medical Product Administration (NMPA) and National Healthcare Security Administration (NHSA) and KOLs of domestic and foreign pharmaceutical R&D gathered around to demonstrate the latest encouraging policy and investment trend.
✦KOLs of Global Financial Institution
KOLs from leading stock exchanges such as HKEX, NASDAQ and London Stock Exchange delivered speeches and participated in panels.
✦Experts Leading Global Pharmaceutical R&D
Chen Lieping, Co-Director of the Cancer Immunology Program at the Yale Cancer Center, Liu Yongjun, Global Head of Research of Sanofi and other company representatives and scholars gathered around to share the latest outcomes of pharmaceutical R&D.
✦Top Level Academic Journal
Global editors of Nature and Nature Drug Discovery participated in the conference and had fruitful communication with domestic pharmaceutical companies.
For more information of previous CBIIC, please visit the website.
Joint Communication of Domestic and Foreign Stakeholders
Ø Chairman/CEO & senior management from pharmaceutical companies
Ø Representatives of regulatory and government affairs, global strategy, drug R&D and business development
Ø Representatives seeking cooperation with domestic and international pharmaceutical R&D institutions and innovative enterprises
Ø Representatives from investment companies and financial institutions committing to pharmaceutical innovation
Ø Officials from government and foreign embassies
Ø Top leading scientists and researchers